» Articles » PMID: 19291325

Procalcitonin Kinetics Within the First Days of Sepsis: Relationship with the Appropriateness of Antibiotic Therapy and the Outcome

Overview
Journal Crit Care
Specialty Critical Care
Date 2009 Mar 18
PMID 19291325
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Management of the early stage of sepsis is a critical issue. As part of it, infection control including appropriate antibiotic therapy administration should be prompt. However, microbiological findings, if any, are generally obtained late during the course of the disease. The potential interest of procalcitonin (PCT) as a way to assess the clinical efficacy of the empirical antibiotic therapy was addressed in the present study.

Methods: An observational cohort study including 180 patients with documented sepsis was conducted in our 15-bed medical intensive care unit (ICU). Procalcitonin measurement was obtained daily over a 4-day period following the onset of sepsis (day 1 (D1) to D4). The PCT time course was analyzed according to the appropriateness of the first-line empirical antibiotic therapy as well as according to the patient outcome.

Results: Appropriate first-line empirical antibiotic therapy (n = 135) was associated with a significantly greater decrease in PCT between D2 and D3 (DeltaPCT D2-D3) (-3.9 (35.9) vs. +5.0 (29.7), respectively; P < 0.01). In addition, DeltaPCT D2-D3 was found to be an independent predictor of first-line empirical antibiotic therapy appropriateness. In addition, a trend toward a greater rise in PCT between D1 and D2 was observed in patients with inappropriate antibiotics as compared with those with appropriate therapy (+5.2 (47.4) and +1.7 (35.0), respectively; P = 0.20). The D1 PCT level failed to predict outcome, but higher levels were measured in the nonsurvivors (n = 51) when compared with the survivors (n = 121) as early as D3 (40.8 (85.7) and 21.3 (41.0), respectively; P = 0.04). Moreover, PCT kinetics between D2 and D3 were also found to be significantly different, since a decrease >or= 30% was expected in the survivors (log-rank test, P = 0.04), and was found to be an independent predictor of survival (odds ratio = 2.94; 95% confidence interval 1.22 to 7.09; P = 0.02).

Conclusions: In our study in an ICU, appropriateness of the empirical antibiotic therapy and the overall survival were associated with a greater decline in PCT between D2 and D3. Further studies are needed to assess the utility of the daily monitoring of PCT in addition to clinical evaluation during the early management of sepsis.

Citing Articles

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024.

Shime N, Nakada T, Yatabe T, Yamakawa K, Aoki Y, Inoue S Acute Med Surg. 2025; 12(1):e70037.

PMID: 39996161 PMC: 11848044. DOI: 10.1002/ams2.70037.


Predicting Mortality in Sepsis: The Role of Dynamic Biomarker Changes and Clinical Scores-A Retrospective Cohort Study.

Varga N, Benea A, Suba M, Bota A, Avram C, Boru C Diagnostics (Basel). 2024; 14(17).

PMID: 39272757 PMC: 11393859. DOI: 10.3390/diagnostics14171973.


Assessment value of interleukin-6, procalcitonin, and C-reactive protein early kinetics for initial antibiotic efficacy in patients with febrile neutropenia: A prospective study.

Zheng H, Luo Z, Yi Y, Liu K, Huo Z, You Y Cancer Med. 2024; 13(13):e7307.

PMID: 38967137 PMC: 11224913. DOI: 10.1002/cam4.7307.


Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Infections.

Campogiani L, Crea A, Minardi M, Ansaldo L, Coppola L, Compagno M Open Forum Infect Dis. 2023; 10(12):ofad627.

PMID: 38156051 PMC: 10753918. DOI: 10.1093/ofid/ofad627.


Respiratory Immune Responses during Infection and Pollution Inhalation.

McCarthy C, Geraghty P Medicina (Kaunas). 2023; 59(2).

PMID: 36837444 PMC: 9959294. DOI: 10.3390/medicina59020242.


References
1.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B . Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2002; 345(19):1368-77. DOI: 10.1056/NEJMoa010307. View

2.
Nylen E, Whang K, Snider Jr R, Steinwald P, White J, Becker K . Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998; 26(6):1001-6. DOI: 10.1097/00003246-199806000-00015. View

3.
Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1):84-93. DOI: 10.1164/rccm.200512-1922OC. View

4.
Schroder J, Staubach K, Zabel P, Stuber F, Kremer B . Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg. 1999; 384(1):33-8. DOI: 10.1007/s004230050170. View

5.
Clech C, Ferriere F, Karoubi P, Fosse J, Cupa M, Hoang P . Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004; 32(5):1166-9. DOI: 10.1097/01.ccm.0000126263.00551.06. View